US3734953A - Tris-triiodoisophthalamic acids and derivatives - Google Patents

Tris-triiodoisophthalamic acids and derivatives Download PDF

Info

Publication number
US3734953A
US3734953A US00849175A US3734953DA US3734953A US 3734953 A US3734953 A US 3734953A US 00849175 A US00849175 A US 00849175A US 3734953D A US3734953D A US 3734953DA US 3734953 A US3734953 A US 3734953A
Authority
US
United States
Prior art keywords
tris
acid
triiodoisophthalamic
nitrilotrisethylene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US00849175A
Inventor
J Bernstein
K Losee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of US3734953A publication Critical patent/US3734953A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups

Definitions

  • the new compounds of Formula I are produced by COOH COOE I I I CH2) nNHCO NH-C 0 Z I Z O O-NH O-NH-(CH2)r-N I (CHah-NH-CO- NH-C 0 Z wherein Z is an alkyl chain of up to 6 carbon atoms, or a It acting 1 mole of a tris (aminoalkylene) amine with 3 radical of the formula moles of a 3-carboalkoxy-S-nitrobenzoyl halide (prefer- R' ably the chloride) to form compounds of Formula 11 ⁇ N (II) 000R,
  • R is an alkyl chain of up to 6 carbon atoms, and 5 (CH n NH CO N 0 R" is hydrogen or an alkyl chain of up to 6 carbon 0 z) 2 atoms, n is an integer from 2 to 4, and to salts and lower 0 NH(CH2)N alkyl esters of these compounds.
  • These compounds are OHah-NH-CO N01 useful as radiopaque agents. 40
  • This invention relates to new compounds of Formula I OORI (I) C O OH (I: 0 OH I I I CHfl)r-'NHCO NH-COZ I Z 0 O-NH C O--NH--(CH2)u-N I (CH2) B NH CO NH-C 0 Z OOH wherein Z is an alkyl chain of up to 6 carbon atoms or a wherein n is as defined before and R is lower alkyl.
  • This radical of the formula reaction may be efiected in an aqueous alkaline solution.
  • the ester of Formula II is then converted to the free acid by treatment with alkali, such as sodium carbonate, to give compounds of Formula II in which R is hydrogen.
  • the nitro groups are then reduced to amino groups, e.g. catalytically in the presence of a noble metal catalyst such as palladium, to obtain a compound of the Formula III (III) ooorr COOH HzN
  • the acylating agents may be acid anhydrides, such as acetic anhydride or butyric anhydride; acyl halides, such as acetyl chloride or propionyl chloride; substituted carbamoyl halide, such as dimethyl carbamoyl chloride or dibutyl carbamoyl chloride; and isocyanates, such as methyl isocyanate, ethyl isocyanate, hexyl isocyanate, phenyl isocyanate, p-chlorophenyl isocyanate or benzyl isocyanate.
  • acid anhydrides such as acetic anhydride or butyric anhydride
  • acyl halides such as acetyl chloride or propionyl chloride
  • substituted carbamoyl halide such as dimethyl carbamoyl chloride or dibutyl carbamoyl chloride
  • isocyanates such as methyl isocyanate, ethy
  • salts with inorganic or organic bases e.g. alkali or alkaline earth metal hydroxides such as sodium hydroxide or amines such as ammonia or N- methylglucamine or may be converted to esters of lower alkanols, e.g. by treatment of an alkaline solution with a di(lower alkyl) sulfate, or by treatment of the acid with a diazoalkane, such as diazomethane.
  • the salts, especially insoluble salts frequently provide a convenient means for isolating and purifying the product.
  • the new products of Formula I are useful as radiopaque agents for visualization of animal systems or organs, preferably in the form of physiologically acceptable salts such as sodium or methylglucamine salts for the preparation of solutions for intravascular injection for urography and for vasographic techniques such as angiocardiography, arteriography, nephrography and venography.
  • the waterinsoluble esters are useful in visualizing hollow organs and cavities having external orifices through which the contrast preparation can be introduced in preparation for the examination and removal after the examination is completed. Solutions having about 20 to 50% bound iodine, preferably about 37%, may be used, or on a weight basis from about 20 g. to about 75 g. of a compound of Formula I per 100 ml. of water.
  • EXAMPLE 1 (a) Preparation of N,N',N"-(nitrilotrisethylene)tris- (5 )-nitroisophthalamic acid)trimethyl ester To a solution of 1.46 grams of tris(2-aminoethyl)amine in 50 ml. of acetone there is added a solution of 2.52 grams sodium bicarbonate in 50 ml. of water. The sus- COOH pension is cooled to from about 5 to +5 and 7.29 grams of 3-carbomethoxy-S-nitrobenzoyl chloride are added, in small portions, with vigorous stirring during thirty minutes. The reaction mixture is allowed to warm to room temperature and is then stirred for an additional four hours. The solid is filtered by suction and washed with water and alcohol to yield N,N',N"-(nitrilotrisethylene)tris(S-nitroisophthalamic acid)trimethyl ester.
  • N,N',N"-(nitrilotrisethylene)tris(S-aminoisophthalamic acid) To a solution of 7.25 grams of N,N,N"-(nitriolotrisethylene)tris(S-nitroisophthalamic acid) in 30 ml. of N-NaOH solution there are added 75 ml. of Water and 750 mg. of 5% palladium on charcoal catalyst. The mixture is shaken at room temperature at 50 psi. of hydrogen until the absorption of hydrogen is complete. The catalyst is removed by filtration and the aqueous filtrate is acidified with acetic acid.
  • N,N',N"-(nitrilotrisethylene) tris (5-amino-2,4,6- triiodoisophthalamic acid)
  • acetic acid To a mixture of 75 ml. of water and ml. of acetic acid there are added 11.2 grams of N,N',N-(nitrilotrisethylene)tris(S-aminoisophthalamic acid) and the mixture is heated to 50".
  • N,N,N"- (nitrilotrisethylene) tris 5 -acetamido-2,4, 6- triiodoisophthalamic acid) A mixture of 12 grams of N,N',N"-(nitriolotrisethylene)tris(5-amino-2,4,6-triiodoisophthalamic acid), 300 ml. of acetic acid and 30 ml. of acetic anhydride, to which has been added 1 ml. of concentrated H 50 is heated with stirring to reflux. The mixture is refluxed for four hours and then concentrated under reduced pressure to remove most of the solvent. The residue is suspended in water and, after two hours, made strongly acid with 20% hydrochloric acid.
  • N-methylglucamine salt of N,N,N"-(nitrilotrisethylene)tris(S-acetamido-2,4,6-triiodoisophthalamic acid).
  • EXAMPLE 7 A mixture of 5 grams of N,N',N"-(nitrilotrisethylene)- tris(5-amino-2,4,6-triiodoisophthalamic acid), 50 ml. of dimehylformamide and 2 grams of methyl isocyanate is heated on a steam bath for six hours. The dimethylformamide is removed by distillation under reduced pressure and the residue triturated with water to which dilute hydrochloric acid has been added.
  • the precipitated solid is filtered, washed with dilute hydrochloric acid and allowed to air dry to yield the desired N,N',N"-(nitrilotrisethylene)tris[5-(3-methylureido) 2,4,6 triiodoisophthalamic acid].
  • the product may be purified by solution in dilute sodium hydroxide, treatment with decolorizing carbon, filtration and precipitation with dilute hydrochloric acid.
  • EXAMPLE 8 To a mixture of 3.5 grams of N,N',N"- (nitrilotrisethylene)tris(5-amino-2,4,6-triiodoisophthalamic acid), 5 ml. of N-methylmorpholine and 50 ml. of dimethylformamide, there is added, dropwise, with vigorous stirring 1.6 grams of diethylcarbamoyl chloride. The reaction mixture is stirred for one hour at room temperature and is then warmed on a steam bath for eight hours. The dimethylformamide is removed by distillation under reduced pressure and the residue added to 100 ml. of 10% hydrochloric acid.
  • the precipitated solid is filtered, dissolved in 10% sodium hydroxide, filtered and reprecipitated with dilute hydrochloric acid to yield the desired N,'N,N"-(nitrilotrisethylene)tris[5 (3,3 diethylureido) 2,4,6 triiodoisophthalamic acid].
  • Tris-triiodoisophthalamic acid compounds having the formula I I (i? O OH I I CH2) rNH-CO NHC OZ I ZCONH CONH(CH2) r-N I I l (C H2) r-NH-CO NHC OZ O OH wherein Z is an alkyl chain of up to 6 carbon atoms or a radical of the formula wherein R is an alkyl chain of up to 6 carbon atoms and R" is hydrogen or an alkyl chain of up to 6 carbon atoms, and n is an integer from 2 to 4, and to pharmaceutically acceptable basic salts and lower alkyl esters of the compounds.
  • a sodium salt of a compound of claim 1 1.
  • a compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris(5 acetamido 2,4,6 triiodoisophthalamic acid).
  • a compound of claim 1 having the name N,N,N"- [nitrilo-tris(tetramethylene)]tris(5-acetamido 2,4,6 triiodoisophthalamic acid).
  • a compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris(5 butyramido 2,4,6 triiodoisophthalamic acid).
  • a compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris[5-(3-methylureido) 2,4,6 triiodoisophthalamic acid].
  • a compound of claim 1 having the name N,N,N"- (nitrilotrisethylene)tris[5-(3,3-diethyluredio) 2,4,6 triiodoisophthalamic acid].

Abstract

THIS INVENTION RELATES TO NEW TRIS-TRIIODOISOPHTHALAMIC ACID COMPOUNDS HAVING THE FORMULA

(Z-CO-NH-(2,4,6-TRI(I-),5-(HOOC-)-1,3-PHENYLENE)-CO-NH-

(CH2)N)3-N

WHEREIN Z IS AN ALKYL CHAIN OF UP TO 6 CARBON ATOMS, OR A RADICAL OF THE FORMULA

-N(-R'')-R"

WHEREIN R'' IS AN ALKYL CHAIN OFUP TO 6 CARBON ATOMS, AND R" IS HYDROGEN OR AN ALKYL CHAIN OF UP TO 6 CARBON ATOMS, N IS AN INTEGER FROM 2 TO 4, AND TO SALTS AND LOWER ALKYL ESTERS OF THESE COMPOUNDS. THESE COMPOUND ARE USEFUL AS RADIOPAQUE AGENTS.

Description

"' 3,734,953 Patented May 22, 1973 nifid S ates Patent O wherein R is analkyl chain of up to 6 carbon atoms and 3,734,953 R" is hydrogen or an alkyl chain of up to 6 carbon atoms, TRIS-TRHODOI%%IEII$IAI%IE%\;IC ACIDS and n is an integer from 2 to 4 and to basic salts of these compounds, e.g. alkali metal salts such as for example Jack Bernstem and Kathryn Losee New Brunswick NJ. assi ors to E. R. Squibb & so c. New York, N 5 the sodium or potasslum salts, alkaline earth salts such as,
No Drawing. Filed Aug. 11 1969 Ser. No. 849 175 for example, calcium, ammonium salts and amine salts Int CL C071: 103/30 such as, for example, the N-methylglucamine salt, as well s CL 260 501.11 8 Claims as lower alkyl esters such as, for example, the methyl, ethyl, butyl and hexyl esters, of the new compounds of 10 Formula I. As used in this specification, the term lower ABSTRACT OF THE DISCLOSURE alkyl includes straight and branched chain saturated This invention relates to new tris-triiodoisophthalamic radicals of up to four carbon atoms. acid compounds having the formula The new compounds of Formula I are produced by COOH COOE I I I CH2) nNHCO NH-C 0 Z I Z O O-NH O-NH-(CH2)r-N I (CHah-NH-CO- NH-C 0 Z wherein Z is an alkyl chain of up to 6 carbon atoms, or a It acting 1 mole of a tris (aminoalkylene) amine with 3 radical of the formula moles of a 3-carboalkoxy-S-nitrobenzoyl halide (prefer- R' ably the chloride) to form compounds of Formula 11 \N (II) 000R,
000R R l 3 wherein R is an alkyl chain of up to 6 carbon atoms, and 5 (CH n NH CO N 0 R" is hydrogen or an alkyl chain of up to 6 carbon 0 z) 2 atoms, n is an integer from 2 to 4, and to salts and lower 0 NH(CH2)N alkyl esters of these compounds. These compounds are OHah-NH-CO N01 useful as radiopaque agents. 40
This invention relates to new compounds of Formula I OORI (I) C O OH (I: 0 OH I I I I CHfl)r-'NHCO NH-COZ I Z 0 O-NH C O--NH--(CH2)u-N I (CH2) B NH CO NH-C 0 Z OOH wherein Z is an alkyl chain of up to 6 carbon atoms or a wherein n is as defined before and R is lower alkyl. This radical of the formula reaction may be efiected in an aqueous alkaline solution. The ester of Formula II is then converted to the free acid by treatment with alkali, such as sodium carbonate, to give compounds of Formula II in which R is hydrogen. The nitro groups are then reduced to amino groups, e.g. catalytically in the presence of a noble metal catalyst such as palladium, to obtain a compound of the Formula III (III) ooorr COOH HzN
(CH2) nNHCO OOOH The compounds of Formula III are then iodinated. This may be effected by treating the compounds of Formula III with an iodinating agent, e.g. an iodine halide dissolved in an aqueous potassium chloride (which forms KICl to give compounds of the Formula IV 1v coon (CHzLy-NH-CO NHz O OH The compounds of Formula IV are then treated with an acylating agent to give products of the Formula I. The acylating agents may be acid anhydrides, such as acetic anhydride or butyric anhydride; acyl halides, such as acetyl chloride or propionyl chloride; substituted carbamoyl halide, such as dimethyl carbamoyl chloride or dibutyl carbamoyl chloride; and isocyanates, such as methyl isocyanate, ethyl isocyanate, hexyl isocyanate, phenyl isocyanate, p-chlorophenyl isocyanate or benzyl isocyanate.
These products form salts with inorganic or organic bases, e.g. alkali or alkaline earth metal hydroxides such as sodium hydroxide or amines such as ammonia or N- methylglucamine or may be converted to esters of lower alkanols, e.g. by treatment of an alkaline solution with a di(lower alkyl) sulfate, or by treatment of the acid with a diazoalkane, such as diazomethane. The salts, especially insoluble salts, frequently provide a convenient means for isolating and purifying the product.
The new products of Formula I are useful as radiopaque agents for visualization of animal systems or organs, preferably in the form of physiologically acceptable salts such as sodium or methylglucamine salts for the preparation of solutions for intravascular injection for urography and for vasographic techniques such as angiocardiography, arteriography, nephrography and venography. The waterinsoluble esters are useful in visualizing hollow organs and cavities having external orifices through which the contrast preparation can be introduced in preparation for the examination and removal after the examination is completed. Solutions having about 20 to 50% bound iodine, preferably about 37%, may be used, or on a weight basis from about 20 g. to about 75 g. of a compound of Formula I per 100 ml. of water.
The following examples are illustrative of the invention. All temperatures are on the centigrade scale.
EXAMPLE 1 (a) Preparation of N,N',N"-(nitrilotrisethylene)tris- (5 )-nitroisophthalamic acid)trimethyl ester To a solution of 1.46 grams of tris(2-aminoethyl)amine in 50 ml. of acetone there is added a solution of 2.52 grams sodium bicarbonate in 50 ml. of water. The sus- COOH pension is cooled to from about 5 to +5 and 7.29 grams of 3-carbomethoxy-S-nitrobenzoyl chloride are added, in small portions, with vigorous stirring during thirty minutes. The reaction mixture is allowed to warm to room temperature and is then stirred for an additional four hours. The solid is filtered by suction and washed with water and alcohol to yield N,N',N"-(nitrilotrisethylene)tris(S-nitroisophthalamic acid)trimethyl ester.
(b) N,N',N"-(nitrilotrisethylene)tris(S-nitroisophthalamic acid) To a suspension of 3.84 grams of N,N,N"-(nitrilotrisethylene)tris(5-nitroisophthalamic acid)trimethyl ester in a mixture of 60 ml. of acetone and 60 ml. of water there are added 1.59 grams of sodium carbonate. The mixture is stirred at room temperature for one hour and then heated on a steam bath for 2 /2 hours. The clear solution is concentrated under reduced pressure to remove the acetone and the aqueous solution is treated with decolorizing carbon. The solution is filtered and the filtrate is made strongly acid with 20% hydrochloric acid. The precipitated solid is filtered and washed with water to yield the desired N,N',N"-(nitrilotrisethylene)tris(5-nitroisophthalamic acid).
(0) N,N',N"-(nitrilotrisethylene)tris(S-aminoisophthalamic acid) To a solution of 7.25 grams of N,N,N"-(nitriolotrisethylene)tris(S-nitroisophthalamic acid) in 30 ml. of N-NaOH solution there are added 75 ml. of Water and 750 mg. of 5% palladium on charcoal catalyst. The mixture is shaken at room temperature at 50 psi. of hydrogen until the absorption of hydrogen is complete. The catalyst is removed by filtration and the aqueous filtrate is acidified with acetic acid. The precipitated solid is filtered and washed with water to yield the desired N,N,N"- (nitrilotrisethylene tris S-aminoisophthalamic acid) (d) N,N',N"-(nitrilotrisethylene) tris (5-amino-2,4,6- triiodoisophthalamic acid) To a mixture of 75 ml. of water and ml. of acetic acid there are added 11.2 grams of N,N',N-(nitrilotrisethylene)tris(S-aminoisophthalamic acid) and the mixture is heated to 50". To this mixture there are then added 66 ml. of a 2.68 M KICl solution and the reaction mixture heated at 50-55 for 24 hours. An additional 33 ml. of 2.68 M KIClsolution are then added and the reaction mixtures heated for an additional 65 hours. The cooled reaction mixture is poured onto cracked ice and the precipitated solid is filtered and washed with water. The product is dissolved in alcohol, treated with decolorizing carbon and recovered by concentration of the solvent. For further purification the product is adsorbed on an alumina column and eluted with aqueous alcoholic ammonia. The elutes are acidified and concentrated under reduced pressure to yield the desired product.
(e) N,N,N"- (nitrilotrisethylene) tris 5 -acetamido-2,4, 6- triiodoisophthalamic acid) A mixture of 12 grams of N,N',N"-(nitriolotrisethylene)tris(5-amino-2,4,6-triiodoisophthalamic acid), 300 ml. of acetic acid and 30 ml. of acetic anhydride, to which has been added 1 ml. of concentrated H 50 is heated with stirring to reflux. The mixture is refluxed for four hours and then concentrated under reduced pressure to remove most of the solvent. The residue is suspended in water and, after two hours, made strongly acid with 20% hydrochloric acid. The solid is filtered and washed with dilute hydrochloric acid. After air drying it is then washed with ether and finally dried at under reduced pressure for 24 hours to yield the desired N,N',N- (trinitrilotrisethylene)tris(S-acetamido 2,4,6 triiodoisophthalamic acid).
EXAMPLE 2 Following the procedure of Example 1, but substituting an equivalent amount of tris(3-aminopropyl)amine for the tris(2-aminoethyl)amine, there is obtained the desired N,N',N" [nitrilotris(trimethylene) ]tris(5 acetamido- 2,4,6-triiodoisophthala-mic acid).
EXAMPLE 3 Following the procedure of Example 1 but substituting an equivalent amount of tris(4-aminobutyl)amine for the tris(2-aminoefl1yl)amine, there is obtained the desired N, N,N"-]nitrilotris(tetramethylene)]tris(5 acetamido-2,4, -triiodoisophthalamic acid).
EXAMPLE 4 Following the procedure of Example 1 but substituting an equivalent amount of butyric anhydride for the acetic anhydride and butyric acid for the acetic acid, there is obtained the desired N,N',N"-(nitrilotnisethylene)tris(5- butyramido-2,4,6-triiodoisophthalamic acid).
EXAMPLE 5 To a solution of 3 grams of N,N',N"-(nitrilotrisethylene)-tris (5-acetamido-2,4,6-triiodoisophthalamic acid) in 50 ml. of dimethylformamide there is added slowly, with vigorous stirring, an excess of a solution of diazomethane in ether. The mixture is stirred for two hours, a few drops of acetic acid are added to destroy the excess diazomethane and the solvents removed by concentration under reduced pressure. The residue is suspended in dilute sodium hydroxide and the insoluble trimethyl ester of N,N',N"- (nitrilotrisethylene)tris (5 acetamido-2,4,6-triiodoisophthalamic acid) recovered by filtration.
EXAMPLE 6 To a suspension of 189.5 grams of N,N',N"-(nitrilotrisethylene)tris(5 acetamido-2,4,6-triiodoisophthalamic acid in 1.5 liters of water there is added 300 ml. of N-NaOH solution and the resulting solution lyophilized to yield the desired trisodium salt of N,N',N"-(nitrilotrisethylene)tris(5 acetamido-2,4,6-triiodoisophthalamic acid).
Similarly, by using an equivalent amount of N-methylglucamine there is obtained the desired N-methylglucamine salt of N,N,N"-(nitrilotrisethylene)tris(S-acetamido-2,4,6-triiodoisophthalamic acid).
EXAMPLE 7 A mixture of 5 grams of N,N',N"-(nitrilotrisethylene)- tris(5-amino-2,4,6-triiodoisophthalamic acid), 50 ml. of dimehylformamide and 2 grams of methyl isocyanate is heated on a steam bath for six hours. The dimethylformamide is removed by distillation under reduced pressure and the residue triturated with water to which dilute hydrochloric acid has been added. The precipitated solid is filtered, washed with dilute hydrochloric acid and allowed to air dry to yield the desired N,N',N"-(nitrilotrisethylene)tris[5-(3-methylureido) 2,4,6 triiodoisophthalamic acid]. The product may be purified by solution in dilute sodium hydroxide, treatment with decolorizing carbon, filtration and precipitation with dilute hydrochloric acid.
EXAMPLE 8 To a mixture of 3.5 grams of N,N',N"- (nitrilotrisethylene)tris(5-amino-2,4,6-triiodoisophthalamic acid), 5 ml. of N-methylmorpholine and 50 ml. of dimethylformamide, there is added, dropwise, with vigorous stirring 1.6 grams of diethylcarbamoyl chloride. The reaction mixture is stirred for one hour at room temperature and is then warmed on a steam bath for eight hours. The dimethylformamide is removed by distillation under reduced pressure and the residue added to 100 ml. of 10% hydrochloric acid. The precipitated solid is filtered, dissolved in 10% sodium hydroxide, filtered and reprecipitated with dilute hydrochloric acid to yield the desired N,'N,N"-(nitrilotrisethylene)tris[5 (3,3 diethylureido) 2,4,6 triiodoisophthalamic acid].
6 EXAMPLE 9 A solution suitable for use in intravenous uro'graphy has the following composition (per ml.):
N,N',N"-(nitrilotrisethylene)tris (5 acetamido-2,
4,6-triiodoisophthalamic acid), sodium salt grams 67 Sodium citrate (as bulfer) mg 320 Disodium ethylenediaminetetracetic acid dihydrate acid dihyrate (sequestering agent) mg 40 Methylparaben (as preservative) mg 100 Propylparaben (as preservative) mg 30 The solution is prepared by dissolving the sodium salt in a limited amount of sterile water, adjusting the pH to about 7, adding the rest of the components and adjusting the final volume to 100 ml.
What is claimed is:
1. Tris-triiodoisophthalamic acid compounds having the formula I I (i? O OH I I CH2) rNH-CO NHC OZ I ZCONH CONH(CH2) r-N I I l (C H2) r-NH-CO NHC OZ O OH wherein Z is an alkyl chain of up to 6 carbon atoms or a radical of the formula wherein R is an alkyl chain of up to 6 carbon atoms and R" is hydrogen or an alkyl chain of up to 6 carbon atoms, and n is an integer from 2 to 4, and to pharmaceutically acceptable basic salts and lower alkyl esters of the compounds.
2. A sodium salt of a compound of claim 1.
3. An N-methylglucamine salt of a compound of claim 1.
4. A compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris(5 acetamido 2,4,6 triiodoisophthalamic acid).
5. A compound of claim 1 having the name N,N,N"- [nitrilo-tris(tetramethylene)]tris(5-acetamido 2,4,6 triiodoisophthalamic acid).
6. A compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris(5 butyramido 2,4,6 triiodoisophthalamic acid).
7. A compound of claim 1 having the name N,N',N"- (nitrilotrisethylene)tris[5-(3-methylureido) 2,4,6 triiodoisophthalamic acid].
8. A compound of claim 1 having the name N,N,N"- (nitrilotrisethylene)tris[5-(3,3-diethyluredio) 2,4,6 triiodoisophthalamic acid].
References Cited UNITED STATES PATENTS 3,541,141 11/1970 Bernstein et a1. 260518 A HENRY R. JILES, Primary Examiner L. A. THAXTON, Assistant Examiner US. Cl. X.R.
US00849175A 1969-08-11 1969-08-11 Tris-triiodoisophthalamic acids and derivatives Expired - Lifetime US3734953A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84917569A 1969-08-11 1969-08-11

Publications (1)

Publication Number Publication Date
US3734953A true US3734953A (en) 1973-05-22

Family

ID=25305246

Family Applications (1)

Application Number Title Priority Date Filing Date
US00849175A Expired - Lifetime US3734953A (en) 1969-08-11 1969-08-11 Tris-triiodoisophthalamic acids and derivatives

Country Status (5)

Country Link
US (1) US3734953A (en)
CH (1) CH530373A (en)
DE (1) DE2039214A1 (en)
FR (1) FR2068481B1 (en)
GB (1) GB1324257A (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS514132A (en) * 1974-05-31 1976-01-14 Guerbet Lab Andre
US3991105A (en) * 1973-05-18 1976-11-09 Nyegaard & Co. A/S Process for the preparation of 3-acetamido-5-amino-2,4,6-triiodobenzoic acid
US5192798A (en) * 1988-02-19 1993-03-09 The Upjohn Company Lipophilic polyamines useful for treating hypercholesterolemia
US20070128120A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Organic radiographic contrasting agents for medical devices
WO2009005364A1 (en) * 2007-06-29 2009-01-08 Ge Healthcare As Contrast agents
WO2009005365A1 (en) * 2007-06-29 2009-01-08 Ge Healthcare As Contrast agents
CN101379023A (en) * 2006-02-15 2009-03-04 通用电气医疗集团股份有限公司 Contrast agents

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781338A (en) * 1971-02-08 1973-12-25 Mallinckrodt Chemical Works Nitrilotriacyltriimino-tris-(2,4,6-triiodobenzoic acid)compounds
FR2703055B1 (en) * 1993-03-22 1995-07-07 Guerbet Sa New polyiodinated compounds, their preparation and their use as contrast agents for radiology.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541141A (en) * 1967-06-29 1970-11-17 Squibb & Sons Inc Bis-triiodoisophthalamic acid compounds

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991105A (en) * 1973-05-18 1976-11-09 Nyegaard & Co. A/S Process for the preparation of 3-acetamido-5-amino-2,4,6-triiodobenzoic acid
JPS514132A (en) * 1974-05-31 1976-01-14 Guerbet Lab Andre
US4014986A (en) * 1974-05-31 1977-03-29 Laboratoires Andre Guerbet X-ray contrast media
JPS613779B2 (en) * 1974-05-31 1986-02-04 Guerbet Lab Andre
US5192798A (en) * 1988-02-19 1993-03-09 The Upjohn Company Lipophilic polyamines useful for treating hypercholesterolemia
EP1795209A2 (en) 2005-12-07 2007-06-13 Cordis Corporation Organic radiographic contrasting agents for medical devices
US20070128120A1 (en) * 2005-12-07 2007-06-07 Zhao Jonathon Z Organic radiographic contrasting agents for medical devices
EP1795209A3 (en) * 2005-12-07 2008-01-23 Cordis Corporation Organic radiographic contrasting agents for medical devices
US7407647B2 (en) * 2005-12-07 2008-08-05 Cordis Corporation Organic radiographic contrasting agents for medical devices
CN101379023A (en) * 2006-02-15 2009-03-04 通用电气医疗集团股份有限公司 Contrast agents
WO2009005364A1 (en) * 2007-06-29 2009-01-08 Ge Healthcare As Contrast agents
WO2009005365A1 (en) * 2007-06-29 2009-01-08 Ge Healthcare As Contrast agents
US20100183522A1 (en) * 2007-06-29 2010-07-22 Lars-Goran Wistrand Contrast agents
US20100189656A1 (en) * 2007-06-29 2010-07-29 Lars-Goran Wistrand Contrast agents

Also Published As

Publication number Publication date
GB1324257A (en) 1973-07-25
FR2068481A1 (en) 1971-08-27
DE2039214A1 (en) 1971-02-25
CH530373A (en) 1972-11-15
FR2068481B1 (en) 1974-02-22

Similar Documents

Publication Publication Date Title
CA2376497C (en) Bicyclic polyaminoacid metal complexes, method for preparing same and use in medical imaging
HU182684B (en) New, non-ionic x-ray contrast materials
CA1071228A (en) X-ray contrast media
HU185979B (en) Process for preparing triazoles, oxa- and thiadiazoles
US3097228A (en) Derivatives of 2, 4, 6-trhodobenzoyloxyalkanoic acids and preparation thereof
JPH0825977B2 (en) N- (2 ''-aminophenyl) -benzamide derivative, process for producing the same and pharmaceutical composition containing the same
US3734953A (en) Tris-triiodoisophthalamic acids and derivatives
JPS6313428B2 (en)
HU218083B (en) Novel polyiodinated compounds as radiological contrast agents and process to prepare them
DE1695897A1 (en) N-acyl-sydnonimine derivatives
US3409662A (en) 3, 3'-diamino-5, 5'-dicarboxy-hexaiodocarbanilides and derivatives
US3914294A (en) 3,5-Disubstituted-2,4,6-triiodobenzoic acids
RU2060246C1 (en) Triiodine-5-aminoisophthalic diamides, method for their production and radiological composition
DE2207950C3 (en) Triiodoisophthalic acid monoamino acid amides, process for their preparation and X-ray contrast media containing these compounds
US3340298A (en) Phenylalkanolamine derivatives
US2543345A (en) Method of preparing glutamic acid amides
US3541141A (en) Bis-triiodoisophthalamic acid compounds
US3660469A (en) Bis-triiodoisophthalamic acid compounds
US3910989A (en) N-triiodobenzyl-carbamic acid derivatives
DE69908756T2 (en) MATRIX metalloproteinase inhibitors
US3306927A (en) N,n'-bis(3-amino-5-carboxy-2,4,6-trhodophenyl)-lower-alkanedioic acid amides and derivatives
FI67078C (en) NYA ROENTGENKONTRASTMEDEL OCH FOERFARANDE FOER DERAS FRAMSTAELLNING
KR100194506B1 (en) Nonionic iodide compound, preparation method thereof and contrast agent containing the same
US3819821A (en) X-ray opacifiers
US3666800A (en) Substituted triiodoisophthalamic acids